z-logo
Premium
Effects of norepinephrine on NMDA‐induced neurotoxicity in cerebellar granular cell culture of rat pups
Author(s) -
Gepdiremen A,
Sönmez S,
Kiziltunç A,
Ikbal M,
Erman F,
Düzenli S.
Publication year - 1998
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1998.tb00980.x
Subject(s) - norepinephrine , nmda receptor , medicine , neurotoxicity , population , endocrinology , catecholamine , anesthesia , toxicity , dopamine , receptor , environmental health
Summary— In this study, norepinephrine was tested in 0.1, 1, 10, 25 and 50 μM doses in 100 μM NMDA toxicity on cerebellar granular cell culture of rats. NMDA in 100 μM concentration induced cell death significantly with respect to controls. Death cell population was 1.08 ± 0.44% in control and 22.15 ± 2.46% in 100 μM NMDA ( P < 0.0001). None of the norepinephrine concentrations administrated 15 min prior to NMDA was able to reduce death cell scores to control levels. Results were 8.75 ± 0.83% in 0.1 4mUM, 7.0 ± 1.01% in 1 μM, 17.25 ± 1.31% in 10 μM, 35.5 ± 1.38% in 25 μM and 17.9 ± 1.72% in 50 μM norepinephrine plus 100 μM NMDA administrated groups ( P < 0.0001 for all with respect to control). Labetalol, as an alpha and beta blocker in 0.5 μM concentration which was given 15 min prior to norepinephrine was able to block the effects of it. In comparison with 100 μM NMDA administered group, only low doses of norepinephrine reduced the death cell scores significantly (for 0.1 and 1 μM norepinephrine plus NMDA groups; P < 0.0001). For 10 and 50 μM norepinephrine plus NMDA groups, death cell scores were found statistically insignificant from the NMDA‐administered group ( P > 0.05 for both) while for the 25 μM norepinephrine plus NMDA group, the death cell score was found to be statistically increased ( P < 0.0001).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here